| Name | Title | Contact Details |
|---|
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com
FM Global is a Rhode Island-based insurance company that specializes in property insurance, risk consulting and loss prevention for businesses.
Palmer & Cay is a specialty commercial insurance and employee benefits brokerage and consulting firm. We specialize in industry niches with complex risks and extensive service needs, delivering high value services to clients on a worldwide basis. Our highly synchronized teams bring deep experience and strategic talents to each clients needs. Our focus is on middle market to large corporate clients, delivering Property & Casualty and Employee Benefits consulting & brokerage services, including risk analysis, claims consulting, program design, marketing and administration, and risk control. When losses occur, we surround our clients with intense claim advocacy services. Building upon a culture that was started nearly 150 years ago, we understood then, and today still believe, that people are what make an organization successful. To deliver on our promise to consistently deliver "exceptional client service", we know we have to attract the best, most passionate, and technical people in our business. Combining this fundamental approach with a culture where the client is at the center of everything we do allows us to create extraordinary results for our clients.
We are brewing up something incredible here at HTeaO. In January of 2018 we launched our franchise prototype store in Midland, TX. Our desire is to provide ultra-premium Tea, Water and related products that give people safe and healthy food choices in a fun and clean environment. We are committed to providing the absolute best quality iced tea money can buy in a retail environment. With the incredible support of our customers we are entering into a season where we teach, train and mentor franchisees in growing their own successful business. Would you like to join us?
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.